Acculturation and hepatic steatosis among individuals of Hispanic ancestry
- PMID: 38961876
- PMCID: PMC11221846
- DOI: 10.1097/CLD.0000000000000240
Acculturation and hepatic steatosis among individuals of Hispanic ancestry
Conflict of interest statement
Alan Bonder consults and received grants from Chemomab, CymaBay, Ipsen, and GlaxoSmithKline. He consults for GuidePoint and Intercept/Alfasigma. He received grants from CARA Therapeutics, GENFIT, Gilead, Intercept, and Mirium. He has other interests with AASLD and Pfizer. The remaining authors have no conflicts to report.
References
-
- Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. . The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851–861. - PubMed
-
- Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int. 2021;41:1290–1293. - PubMed
-
- Lopez-Class M, Castro FG, Ramirez AG. Conceptions of acculturation: A review and statement of critical issues. Soc Sci Med. 2011;72:1555–1562. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
